CA3151879A1 — Tenofovir alafenamide acesulfamate salt
Assigned to Apotex Inc · Expires 2023-09-14 · 3y expired
What this patent protects
The present invention provides a novel tenofovir alafenamide acesulfamate salt, a crystalline form thereof, compositions and processes for its preparation, and its use in the treatment of a human immunodeficiency virus (HIV) infection or a hepatitis B virus (HBV) infection.
USPTO Abstract
The present invention provides a novel tenofovir alafenamide acesulfamate salt, a crystalline form thereof, compositions and processes for its preparation, and its use in the treatment of a human immunodeficiency virus (HIV) infection or a hepatitis B virus (HBV) infection.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.